

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. 6297.1cp/ PHRM-0295	Serial No. 09/693,746
		Applicant Lowery et al.	
		Filing Date October 20, 2000	Group 1623 1646
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
RLi	/AA	Allen et al., "Modulation of CD4 by Suramin", <i>Clin. Exp. Immunol.</i> , 1993, Vol. 91, pp. 141-156	
	AB	Altschul et al., "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs," <i>Nucl. Acids Res.</i> , 1997, 25(17), 3389-3402	
	AC	Altschul et al., "Basic Local Alignment Search Tool," <i>J. Mol. Biol.</i> , 1990, 215, 403-410	
	/AD	Anafi et al., "Tyrophostin-Induced Inhibition of p210 ^{bcr-abl} Tyrosine Kinase Activity Induces K562 to Differentiate", <i>Blood</i> , 1993, Vol. 82, No. 12, pp. 3524-3529	
	AE	Anderson, W. F., "Human gene therapy," <i>Science</i> , 1992, 256, 808-813	
	/AF	Aukrust et al., "Enhanced Levels of Soluble and Membrane-Bound CD40 Ligand in Patients with Unstable Angina. Possible Reflection of T Lymphocyte and Platelet Involvement in the Pathogenesis of Acute Coronary Syndromes", <i>Circulation</i> , 1999, Vol. 100, pp. 614-620	
	AG	Ausubel, et al. (Eds.), "Chapter 6, Screening of recombinant DNA libraries," <i>Current Protocols in Molecular Biology</i> , 1994, John Wiley & Sons, 6.0.1-6.4.10	
	/AH	Baidur et al., "Selective fluorescent ligands for pharmacological receptors," <i>Drug Dev. Res.</i> , 1994, 33, 373-398	
	/AI	Baker et al., "Induction of Acetylcholine Receptor Clustering by Native Polystyrene Beads. Implication of an Endogenous Muscle-derived Signalling System", <i>J. Cell Sci.</i> , 1992, Vol. 102, pp. 543-555	
	/AJ	Barker et al., "In-Vitro Activity of Non-glutamate Containing Quinazoline-based Thymidylate Synthase Inhibitors", <i>Proc. of Am. Assoc. for Cancer Res.</i> , 1991, Vol. 32, page 327	
	AK	Benoist et al., "In vivo sequence requirements of the SV40 early promoter region," <i>Nature</i> , 1981, 290, 304-310	
RLi	/AL	Bertino, <i>Cancer Res.</i> , "Toward Improved Selectivity in Cancer Chemotherapy: The Richard and Hinda Rosenthal Foundation Award Lecture", 1979, Vol. 3, pp. 293-304	
EXAMINER <i>Rushing L</i>		DATE CONSIDERED 9/30/2006	

Form PTO-1449 Modified		Docket No. 6297.1cp/ PHRM-0295	Serial No. 09/693,746
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Lowery et al.	
		Filing Date October 20, 2000	Group 1623 1646
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
RLi	/AM	Bilder et al., "Tyrophostins Inhibit PDGF-induced DNA Synthesis and Associated Early Events in Smooth Muscle Cells", <i>Amer. Physiol. Soc.</i> , 1991, pp. 6363-6143:C721-C730	
	/AN	Birgul, N. et al., "Reverse physiology in <i>Drosophila</i> : Identification of a novel allatostatin-like neuropeptide and its cognate receptor structurally related to the mammalian somatostatin/galanin/opioid receptor family", <i>The EMBO Journal</i> , 1999, 18(21), 5892-5900	
	/AO	Bohm, S. K., et al., "Regulatory mechanisms that modulate signalling by G-protein-coupled receptors," <i>Biochem. J.</i> , 1997, 322, 1-18	
	AP	Bossé, R., et al., "Development of nonseparation binding and functional assays for G protein-coupled receptors for high throughput screening: Pharmacological characterization of the immobilized CCR5 receptor on FlashPlate®," <i>J. Biomolecular Screening</i> , 1998, 3(4), 285-292	
	/AQ	Boulton, T. G., et al., "ERKs: A family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF," <i>Cell</i> , 1991, 65, 663-675	
	/AR	Brunton, V. G., et al., <i>Proceedings of Amer. Assoc. Cancer Res.</i> , No. 3335, 1992, 33, 558	
	/AS	Bryckaert, M., et al., "Inhibition of platelet-derived growth factor-induced mitogenesis and tyrosine kinase activity in cultured bone marrow fibroblasts by tyrophostins," <i>Experimental Cell Research</i> , 1992, 199, 255-261	
	/AT	Burke, T. R., et al., "Bicyclic compounds as ring-constrained inhibitors of protein-tyrosine kinase p56 ^{lck} ," <i>J. Med. Chem.</i> , 1993, 36(4), 425-432	
	/AU	Burke, T. R., et al., "Arylamides of hydroxylated isoquinolines as protein-tyrosine kinase inhibitors," <i>BioOrganic Med. Chem. Ltrs.</i> , 1992, 2(12), 1771-1774	
RLi	/AV	Capecchi, M. R., "Altering the genome by homologous recombination," <i>Science</i> , 1989, 244, 1288-1292	
EXAMINER		Rui-Liang Li	DATE CONSIDERED 9/20/2006

Form PTO-1449 Modified		Docket No. 6297.1cp/ PHRM-0295	Serial No. 09/693,746
List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Applicant Lowery et al.	
		Filing Date October 20, 2000	Group 1623-1646
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
RLi	✓AW	Chambers, R. C., et al., "Thrombin stimulates fibroblast procollagen production via proteolytic activation of protease-activated receptor 1," <i>Biochem J.</i> , 1998, 333, 121-127	
	✓AX	Choo, Y., et al., "Promoter-specific activation of gene expression directed by bacteriophage-selected zinc fingers," <i>J. Mol. Biol.</i> , 1997, 273, 525-532	
	✓AY	Cicala, C., et al., "Bronchoconstrictor effect of thrombin and thrombin receptor activating peptide in guinea-pigs <i>in vivo</i> ," <i>Br. J. Pharmacol.</i> , 1999, 126, 478-484	
	✓AZ	Cirino, G., et al., "Thrombin functions as an inflammatory mediator through activation of its receptor," <i>J. Exp. Med.</i> , 1996, 183, 821-827	
	✓BA	Colotta, F., et al., "Expression of monocyte chemotactic protein-1 by monocytes and endothelial cells exposed to thrombin," <i>Am. J. Pathol.</i> , 1994, 144, 975-985	
	BB	Cosman, D., et al., "High Level Stable Expression of Human Interleukin-2 receptors in Mouse Cells Generates only Low Affinity Interleukin-2 Binding Sites," <i>Mol. Immunol.</i> , 1986, 23(9), 935-941	
	BC	Cosman, D., et al., "Cloning, sequence and expression of human interleukin-2 receptor," <i>Nature</i> , 1984, 312, 768-771	
	✓BD	Curtin, N. J., et al., "Inhibition of the growth of human hepatocellular carcinoma <i>in vitro</i> and in athymic mice by a quinazoline inhibitor of thymidylate synthase, CB3717," <i>J. Cancer</i> , 1986, 53, 361-368	
	✓BE	Dayoff, in <i>Atlas of Protein Sequence and Structure</i> , 1972, National Biochemical Research Foundation, Washington, D.C., 5, 124	
	✓BF	DiCuccio, M. N., et al., "A functional tethered ligand thrombin receptor is present on human hematopoietic progenitor cells," <i>Exp. Hematol.</i> , 1996, 24, 914-918	
RLi	✓BG	Dolle, R. E., et al., "5,7-dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular β -type platelet-derived growth factor receptor tyrosine kinase," <i>J. Med. Chem.</i> , 1994, 37, 2627-2629	
EXAMINER		Rushing Jr	DATE CONSIDERED 9/30/2006

Form PTO-1449 Modified		Docket No. 6297.1cp/ PHRM-0295	Serial No. 09/693,746
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Lowery et al.	
		Filing Date October 20, 2000	Group 1623 1646
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
RLi	<input checked="" type="checkbox"/> BH	Dong, Z., et al., "Activation of tumoricidal properties in macrophages by lipopolysaccharide requirements protein-tyrosine kinase activity," <i>J. Leukocyte Biology</i> , 1993, 53, 53-60	
	<input checked="" type="checkbox"/> BI	Dong, Z., et al., "Protein tyrosine kinase inhibitors decrease induction of nitric oxide synthase activity in lipopolysaccharide-responsive and lipopolysaccharide-nonresponsive murine macrophages," <i>J. Immunol.</i> , 1993, 151(5), 2717-2724	
	<input checked="" type="checkbox"/> BJ	Donovan, F. M., et al., "Thrombin induces apoptosis in cultured neurons and astrocytes via a pathway requiring tyrosin kinase and RhoA activities," <i>J. Neurosci.</i> , 1997, 17(14), 5316-5326	
	<input checked="" type="checkbox"/> BK	Dooley, C. T., et al., "Binding and <i>in vitro</i> activities of peptides with high affinity for the nociceptin/orphanin FQ receptor, ORL1," <i>J. Pharmacology and Experimental Therapeutics</i> , 1997, 283(2), 735-741	
	<input checked="" type="checkbox"/> BL	Dunlop, J., et al., "Characterization of 5-HT _{1A} receptor functional coupling in cells expressing the human 5-HT _{1A} receptor as assessed with the cytosensor microphysiometer," <i>J. Pharmacological and Toxicological Methods</i> , 1998, 40(1), 47-55	
	<input checked="" type="checkbox"/> BM	Fernandes, D. J., et al., "Biochemical and antitumor effects of 5,8-dideazaisopteroylglutamate, a unique quinazoline inhibitor of thymidylate synthase," <i>Cancer Research</i> , 1983, 43, 1117-1123	
	<input checked="" type="checkbox"/> BN	Ferris, J. P., et al., "Synthesis of Quinazoline Nucleosides from Ribose and Anthranilonitrile. Application of Phase-Transfer Catalysis in Nucleoside Synthesis," <i>J. Org. Chem.</i> , 1979, 44(2), 173-178	
	<input type="checkbox"/> BO	Fields, S., et al., "A novel genetic system to detect protein-protein interactions," <i>Nature</i> , 1989, 340, 245-246	
	<input type="checkbox"/> BP	Fields, S., et al., "The two-hybrid system: an assay for protein-protein interactions," <i>Trends in Genetics</i> , 1994, 10, 286-292	
RLi	<input checked="" type="checkbox"/> BQ	Foote, J., et al., Antibody framework residues affecting the conformation of the hypervariable loops," <i>J. Mol. Biol.</i> , 1992, 224, 487-499	
EXAMINER		Quishang Li	DATE CONSIDERED 9/20/2006

Form PTO-1449 Modified		Docket No. 6297.1cp/ PHRM-0295	Serial No. 09/693,746
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Lowery et al.	
		Filing Date October 20, 2000	Group 1623- 1646
U.S. Department of Commerce Patent and Trademark Office			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
RLi	<input checked="" type="checkbox"/> BR	Frandsen, E. K., et al., "A simple ultrasensitive method for the assay of cyclic AMP and CMP in tissues," <i>Life Sciences</i> , 1976, 529-542	
	<input checked="" type="checkbox"/> BS	Fry, D.W., et al., "A specific inhibitor of the epidermal growth factor receptor tyrosine kinase," <i>Science</i> , 1994, 265, 1093-1095	
	<input checked="" type="checkbox"/> BT	Gazit, A., et al., "Tyrphostins I: Synthesis and biological activity of protein tyrosine kinase inhibitors," <i>J. Med. Chem.</i> , 1989, 32, 2344-2352	
	<input checked="" type="checkbox"/> BU	Gazit, A., et al., "Tyrphostins. 3. Structure-activity relationship studies of α -substituted benzylidenemalononitrile 5-S-aryltyrphostins," <i>J. Med. Chem.</i> , 1993, 36, 3556-3564	
	<input checked="" type="checkbox"/> BV	George, S. E., et al., "Evaluation of a CRE-directed luciferase reporter gene assay as an alternative to measuring cAMP accumulation," <i>J. Biomolecular Screening</i> , 1997, 2(4), 235-240	
	<input checked="" type="checkbox"/> BW	Gerhardt, C. C., et al., "Functional characteristics of heterologously expressed 5-HT receptors," <i>Eur. J. Pharmacology</i> , 1997, 334, 1-23	
	<input checked="" type="checkbox"/> BX	Gill, J. S., et al., "Thrombin induced inhibition of neurite outgrowth from dorsal root ganglion neurons," <i>Brain Res.</i> , 1998, 797, 321-327	
	<input checked="" type="checkbox"/> BY	Grabham, P., et al., "Thrombin receptor activation stimulates astrocyte proliferation and reversal of stellation by distinct pathways: involvement of tyrosine phosphorylation," <i>J. Neurochem</i> , 1995, 64, 583-591	
	<input checked="" type="checkbox"/> BZ	Greisman, H. A., et al., "A general strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites," <i>Science</i> , 1997, 275, 657-661	
	<input checked="" type="checkbox"/> CA	Guerrero, F. D., "Transcriptional Expression of a Putative Tachykinin-like Peptide Receptor Gene From Stable Fly ¹ ," <i>Peptides</i> , 1997, 18(1), 1-5	
RLi	<input checked="" type="checkbox"/> CB	Hauck, R. W., et al., " α -thrombin stimulates contraction of human bronchial rings by activation of protease-activated receptors," <i>Am J. Physiol</i> , 1999, 277, L22-L29	
EXAMINER		Rundling Lr	DATE CONSIDERED 9/30/2006

Form PTO-1449 Modified		Docket No. 6297.1cp/ PHRM-0295	Serial No. 09/693,746
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Lowery et al.	
		Filing Date October 20, 2000	Group 1623 1646
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
RLi	CC	Hauser, F., et al., "Molecular Cloning, Genomic Organization, and Developmental Regulation of a Novel Receptor from <i>Drosophila melanogaster</i> Structurally Related to Members of the Thyroid-stimulating Hormone, Follicle-stimulating Hormone, Luteinizing Hormone/ Choriogonadotropin Receptor Family from Mammals," <i>The J. of Biological Chemistry</i> , 1997, 272(2), 1002-1010	
	CD	Hauser, F. et al., "Molecular Cloning, Genomic Organization, and Developmental Regulation of a Novel Receptor from <i>Drosophila melanogaster</i> Structurally Related to Gonadotropin-Releasing Hormone Receptors from Vertebrates", <i>Biochem. Biophys. Res. Comm.</i> , 1998, 249, 822-828	
	CE	Henikoff, S., et al., "Amino acid substitution matrices from protein blocks," <i>Proc. Natl. Acad. Sci. USA</i> , 1992, 89, 10915-10919	
	CF	Hill, D. C., "Trends in development of high-throughput screening technologies for rapid discovery of novel drugs," <i>Cur. Opinion Drug Disc. Dev.</i> , 1998, 1(1), 92-97	
	CG	Hodgson, J., "Receptor screening and the search for new pharmaceuticals," <i>Bio/Technology</i> , 1992, 10, 973-980	
	CH	Hoffman, M., et al., "Thrombin enhances monocyte secretion of tumor necrosis factor and interleukin-1 beta by two distinct mechanisms," <i>Blood Cells Mol Dis</i> , 1995, 21, 156-167	
	CI	Jackman, A. L., et al., "ICID1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth <i>in vitro</i> and <i>in vivo</i> : A new agent for clinical study," <i>Cancer Research</i> , 1981, 51, 5579-5586	
	CJ	Jayawickreme, C. K., et al., "Gene expression systems in the development of high-throughput screens, <i>Current Opinion in Biotechnology</i> , 1997, 8, 629-634	
	CK	Jones, P. T., et al., "Replacing the complementarity-determining regions in a human antibody with those from a mouse," <i>Nature</i> , 1986, 321, 522-525	
RLi	CL	Jones, T. R., et al., "Quinazoline Antifolates Inhibiting Thymidylate Synthase: Variation of the Amino Acid," <i>J. Med Chem.</i> , 1986, 29, 1114-1118	
EXAMINER		Quining Li	DATE CONSIDERED 9/20/2006

Form PTO-1449 Modified		Docket No. 6297.1cp/ PHRM-0295	Serial No. 09/693,746
List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Applicant Lowery et al.	
		Filing Date March 8, 2001	Group 1646 Not Yet Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
RLi	CM	Kanterman, R. Y., et al., "Transfected D ₂ dopamine receptors mediate the potentiation of arachidonic acid release in chinese hamster ovary cells," <i>Molecular Pharmacology</i> , 1991, 39, 364-369	
	CN	Karlin, S., et al., "Applications and statistics for multiple high-scoring segments in molecular sequences," <i>Proc. Natl. Acad. Sci. USA</i> , 1993, 90, 5873-5787	
	CO	Kaur, G., et al., "Tyrphostin induced growth inhibition: corelation with effect on p210 ^{bcr-abl} autokinase activity in K562 chronic myelogenous leukemia," <i>Anti-Cancer Drugs</i> , 1994, 5, 213-222	
	CP	Kettleborough, C. A., et al., "Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation," <i>Protein Engin.</i> , 1991, 4(7), 773-783	
	CQ	Kim, J., et al., "Design of TATA box-binding protein/zinc finger fusions for targeted regulation of gene expression," <i>Proc. Natl. Acad. Sci. USA</i> , 1997, 94, 3616-3620	
	CR	King, M. J., et al., "Site-specific dephosphorylation and deactivation of the human insulin receptor tyrosine kinase by particulate and soluble phosphotyrosyl protein phosphatases," <i>Biochem. J.</i> , 1991, 275, 413-418	
	CS	Kowal, D., et al., "A [³⁵ S]GTPγS binding assessment of metabotropic glutamate receptor standards in chinese hamster ovary cell lines expressing the human metabotropic receptor subtypes 2 and 4," <i>Neuropharmacology</i> , 1998, 37, 179-187	
	CT	Kuntzweiler, T. A., et al., "Rapid assessment of ligand actions with nicotinic acetylcholine receptors using calcium dynamics and FLIPR," <i>Drug Development Research</i> , 1998, 44(1), 14-20	
	CU	Kuo, M., et al., "Effects of signalling transduction modulators on the transformed phenotypes in v-H-ras-transformed NIH 3T3 cells," <i>Cancer Letters</i> , 1993, 74, 197-202	
RLi	CV	Lajiness et al., "D2 dopamine receptor stimulation of mitogenesis in transfected chinese hamster ovary cells: relationship to dopamine stimulation of tyrosine phosphorylations", <i>J. Pharm. Exp. Ther.</i> , 1993, Vol. 267, No. 3, 1573-1581	
EXAMINER		Runking L	DATE CONSIDERED 9/2/2006

Form PTO-1449 Modified		Docket No. 6297.1cp/ PHRM-0295	Serial No. 09/693,746
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Lowery et al.	
		Filing Date October 20, 2000	Group 1623 1646
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
RLi	<input checked="" type="checkbox"/> CW	Lee, C., et al., "Active-site directed reductive alkylation of xanthine oxidase by imidazo[4,5-g]quinazoline-4,9-diones functionalized with a leaving group," <i>Biochemistry</i> , 1987, 26(23), 7355-7362	
	<input checked="" type="checkbox"/> CX	Lehninger, "Chapter 4, The amino acid building blocks of proteins," <i>Biochemistry</i> , 2 nd Ed., 1975, Worth Publishers, Inc., New York, New York, 71-77	
	<input checked="" type="checkbox"/> CY	Lemus, et al., "Studies of extended quinone methides. Synthesis and physical studies of purine-like monofunctional and bifunctional imidazo[4,5-g]quinazoline reductive alkylating agents," <i>J. Org. Chem.</i> , 1989, 54, 3611-3618	
	<input checked="" type="checkbox"/> CZ	Lenz, C. et al., "Molecular Cloning and Genomic Organization of a Second Probable Allastatin Receptor from <i>Drosophila melanogaster</i> ", <i>Biochem. Biophys. Res. Comm.</i> , 2000, 273, 571-577	
	<input checked="" type="checkbox"/> DA	Lenz, C. et al., <i>Drosophila melanogaster</i> allatostatin G-protein receptor mRNA, complete cds, GenBank Accession No. AF253526, July 14, 2000	
	<input checked="" type="checkbox"/> DB	Lenz, C. et al., "Molecular Cloning and Genomic Organization of an Allatostatin Preprohormone from <i>Drosophila melanogaster</i> ", <i>Biochem. Biophys. Res. Comm.</i> , 2000, 273, 1126-1131	
	<input checked="" type="checkbox"/> DC	Levitzki, A., "Tyrophostins: tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction," <i>The FASEB J.</i> , 1992, 6, 3275-3282	
	<input checked="" type="checkbox"/> DD	Ley, K., et al., "Synthesen unter verwendung von benzofuroxan," <i>Synthesis</i> , 1975, 415-522 (English abstract)	
	<input checked="" type="checkbox"/> DE	Li, X-J., et al., "Cloning, heterologous expression and developmental regulation of a <i>Drosophila</i> receptor for tachykinin-like peptides," <i>The EMBO Journal</i> , 1991, 10(11), 3221-3229	
	<input checked="" type="checkbox"/> DF	Li, X-J., et al., "Cloning, Functional Expression, and Developmental Regulation of a Neuropeptide Y Receptor from <i>Drosophila melanogaster</i> ," <i>The J. of Biological Chemistry</i> , 1992, 267(1), 9-12	
RLi	<input checked="" type="checkbox"/> DG	Li, X.-J. et al., <i>D. melanogaster</i> neuropeptide receptor mRNA, complete cds, GenBank Accession No. M81490, April 26, 1993	
EXAMINER		Ruixiang Lu	DATE CONSIDERED 9/20/2006

Form PTO-1449 Modified		Docket No. 6297.1cp/ PHRM-0295	Serial No. 09/693,746
List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Applicant Lowery et al.	
		Filing Date October 20, 2000	Group 1623 1646
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
RLi	7	DH	Lin, A. H., et al., "The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin," <i>Antimicrobial Agents and Chemotherapy</i> , 1997, 41(10), 2127-2131
		DI	Liu, Q., et al., "Design of polydactyl zinc-finger proteins for unique addressing within complex genomes," <i>Proc. Natl. Acad. Sci. USA</i> , 1997, 94, 5525-5530
		DJ	Luckow, V. A., et al., "High Level Expression of Nonfused Foreign Genes with Autographa californica Nuclear Polyhedrosis Virus Expression Vectors," <i>Virology</i> , 1989, 170, 31-39
		DK	Luckow, V. A., et al., "Trends in the development of baculovirus expression vectors," <i>Bio/Technology</i> , 1988, 6, 47-55
		DL	Lyall, R. M., et al., "Tyrophostins inhibit epidermal growth factor (EGF)-receptor tyrosine kinase activity in living cells and EGF-stimulated cell proliferation," <i>J. Biol. Chem.</i> , 1989, 264, 14503-14509
		DM	Maguire, M. P., et al., "A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives," <i>J. Med. Chem.</i> , 1994, 37, 2129-2131
		DN	Maxwell, R. J., et al., " ¹⁹ F nuclear magnetic resonance imaging of drug distribution <i>in vivo</i> : The disposition of an antifolate anticancer drug in mice," <i>Magnetic Resonance in Medicine</i> , 1991, 17, 189-196
		DO	McColl, D. J., et al., "Structure-based design of an RNA-binding zinc finger", <i>Proc. Natl. Acad. Sci. (USA)</i> , 1997, Vol. 96, 9521-9526
		DP	Mini, E., et al., "Cytotoxic effects of folate antagonists against methotrexate-resistant human leukemic lymphoblast CCRF-CEM cell lines," <i>Cancer Res.</i> , 1985, 45, 325-330
		DQ	Monnier, D., et al., "NKD, a Developmentally Regulated Tachykinin Receptor in Drosophila," <i>The J. of Biological Chemistry</i> , 1992, 267(2), 1298-1302
RLi		DR	Monnier, D. et al., Drosophila melanogaster tachykinin receptor (NKD) mRNA, complete cds, GenBank Accession No. M77168, April 26, 1993
EXAMINER		Runking Jr	DATE CONSIDERED 9/30/2006

Form PTO-1449 Modified		Docket No. 6297.1cp/ PHRM-0295	Serial No. 09/693,746
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Lowery et al.	
		Filing Date October 20, 2000	Group 1623 1646
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
RLi	DS	Morris, R., et al., "Thrombin receptor expression in rheumatoid and osteoarthritic synovial tissue", <i>Ann. Rheum. Dis.</i> , 1996, Vol. 55, 841-843	
	DT	Morrison, et al., "Genetically engineered antibody molecules," Dixon, F.J., et al. (Eds.), <i>Adv. Immunol.</i> , 1989, 44, 65-92	
	DU	Murphy, A. J., et al., "From DNA to drugs: the orphan G-protein coupled receptors," <i>Cur. Opinion Drug Disc. Dev.</i> , 1998, 1(2), 192-199	
	DV	Myers, P., "Will combinatorial chemistry deliver real medicines," <i>Curr. Opin. Biotechnology</i> , 1997, 8, 701-707	
	DW	Nachman & Homan, in <i>Insect Neuropeptides: Chemistry, Biology and Action</i> , Menn, Kelly & Massler, Eds., 1991, 194-214, American Chemical Society, Washington, DC	
	DX	Nakayama, G. R., "Microplate assays for high-throughput screening," <i>Cur. Opinion Drug Disc. Dev.</i> , 1998, 1, 85-91	
	DY	Naldini, A., et al., "Thrombin modulation of natural killer activity in human peripheral lymphocytes," <i>Cell Immunol</i> , 1996, 172, 35-42	
	DZ	Nambu et al., "Isolation and Characterization of a <i>Drosophila</i> Neuropeptide Gene", <i>Neuron</i> , 1988, 1, 55-61	
	EA	Nichols, R. et al., "Identification and Characterization of a <i>Drosophila</i> Homologue to the Vertebrate Neuropeptide Cholecystokinin", <i>J. Biol. Chem.</i> , 1988, 263, 12167-12170	
	EB	Okayama, H., et al., "A cDNA cloning vector that permits expression of cDNA inserts in mammalian cells," <i>Mol. Cell. Biol.</i> , 1983, 3(2), 280-289	
	EC	Padlan, E. A., "A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties," <i>Molecular Immunol.</i> , 1991, 28(4/5), 489-498	
RLi	ED	Pausch, M. H., "G-protein-coupled receptors in <i>saccharomyces cerevisiae</i> : high-throughput screening assays for drug discovery," <i>Trends in Biotechnology</i> , 1997, 15, 487-494	
EXAMINER		<i>Ruckling Lr</i>	DATE CONSIDERED 9/30/2006

Form PTO-1449 Modified		Docket No. 6297.1cp/ PHRM-0295	Serial No. 09/693,746
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Vogell et al.	
		Filing Date October 20, 2000	Group 1623 1646
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
RL;	EE	Peterson, G., et al., "Genistein and biochanin A inhibit the growth of human prostate cancer cells but not epidermal growth factor receptor tyrosine autophosphorylation," <i>The Prostate</i> , 1993, 22, 335-345	
	EF	Phillips, S. D., et al., "Quino[1,2-c]quinazolines. I. Synthesis of quino[1,2-c]quinazolinium derivatives and the related indazolo[2,3-a]quinoline derivatives as analogs of the antitumor benzol[c]phenanthridine alkaloids," <i>J. Heterocyclic Chem.</i> , 1980, 17(19), 1489-1596	
	EG	Pillemer, G., et al., "Insulin dependence of murine lymphoid T-cell leukemia," <i>Int. J. Cancer</i> , 1992, 50, 80-85	
	EH	Pindon, A., et al., "Thrombin-induced reversal of astricyte stellation is mediated by activation of protein kinase C β -1," <i>Eur. J. Biochem.</i> , 1998, 255, 766-774	
	EI	Posner, I., et al., "Kinetics of inhibition by tyrphostins of the tyrosine kinase activity of the epidermal growth factor receptor and analysis," <i>Molecular Pharmacology</i> , 1993, 45, 673-683	
	EJ	Reece, P. A., et al., "Pharmacokinetics of trimetrexate administered by five-day continuous infusion to patients with advanced cancer," <i>Cancer Research</i> , 1977, 47(11), 2996-2999	
	EK	Rendu, F., et al., "Inhibition of platelet activation by tyrosine kinase inhibitors," <i>Biol. Pharmacology</i> , 1992, 44(5), 881-888	
	EL	Riechmann, L., et al., "Reshaping human antibodies for therapy," <i>Nature</i> , 1988, 332, 323-327	
	EM	Rogers, M. V., "Light on high-throughput screening: fluorescence-based assay technologies," <i>Drug Discovery Today</i> , 1997, 2(4), 156-160	
↓	EN	Sauro, M. D., et al., "Tyrphostin attenuates platelet-derived growth factor-induced contraction in aortic smooth muscle through inhibition of protein tyrosine kinase(s)," <i>J. Pharm. And Experimental Therapeutics</i> , 1993, 267(3), 1119-1125	
RL;	EO	Schroeder, K. S., et al., "FLIPR: A new instrument for accurate, high throughput optical screening," <i>J. Biomolecular Screening</i> , 1996, 1, 75-80	
EXAMINER		<i>Quisling L</i>	DATE CONSIDERED 9/30/2006

Form PTO-1449 Modified		Docket No. 6297.1cp/ PHRM-0295	Serial No. 09/693,746
List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Applicant Lowery et al.	
		Filing Date October 20, 2000	Group 1623- 1646
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
RL _i	EP	Sculier, J. P., et al., "Role of an intensive care unit (ICU) in a medical oncology department," No. 257, <i>Cancer Immunol. And Immunother.</i> , 1986, 23, A65	
	EQ	Segal, D. J., et al., "Toward controlling gene expression at will: Selection and design of zinc finger domains recognizing each of the 5'-GNN-3' DNA target sequences," <i>Proc. Natl. Acad. Sci. USA</i> , 1999, 96, 2758-2763	
	ER	Sikora, E., et al., "Quinazoline CB 3717 and CB 3703 inhibition of folate retention and metabolism in ehrlich ascites carcinoma cells and some organs of the host-mouse," <i>Cancer Letters</i> , 1984, 23, 289-295	
	ES	Sikora, E., et al., "Development of an assay for the estimation of N ¹⁰ -propargyl-5,8-dideazafolic acid polyglutamates in tumor cells," <i>Analytical Biochemistry</i> , 1988, 172, 344-355	
	ET	Sim, L. J., et al., "Identification of opioid receptor-like (ORL1) peptide-stimulated [³⁵ S]GTPγS binding in rat brain," <i>Neuroreport</i> , 1996, 7, 729-733	
	EU	Smith, T. F., et al., "Comparison of biosequences," <i>Adv. Appl. Math.</i> , 1981, 2, 482-489	
	EV	Smith-Swintosky, V. L., et al., "Protease-activated receptor-2 (PAR-2) is present in the rat hippocampus and is associated with neurodegeneration," <i>J. Neurochem.</i> , 1997, 69, 1890-1896	
	EW	Stables, J., et al., "A bioluminescent assay for agonist activity at potentially any G-protein-coupled receptor," <i>Analytical Biochemistry</i> , 1997, 252, 115-126	
	EX	Stratowa, C., et al., "Use of a luciferase reporter system for characterizing G-protein-linked receptors," <i>Current Opinion in Biotechnology</i> , 1995, 6, 574-581	
	EY	Strosberg, et al., "Functional expression of receptors in microorganisms," <i>Trends in Pharmacological Sciences</i> , 1992, 13, 95-98	
	EZ	Strosberg, A. D., et al., "Structure/function relationship of proteins belonging to the family of receptors coupled to GTP-binding proteins," <i>Eur. J. Biochem.</i> , 1991, 196, 1-10	
RL _i	FA	Suidan, H. A., et al., "The thrombin receptor in the nervous system," <i>Semin Thromb Hemost</i> , 1996, 22(2), 125-133	
EXAMINER		<i>Rushling Jr</i>	DATE CONSIDERED 9/30/2006

Form PTO-1449 Modified		Docket No. 6297.1cp/ PHRM-0295	Serial No. 09/693,746
List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Applicant Lowery et al.	
		Filing Date October 20, 2000	Group 1623 1646
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
RLi	FB	Sutherland, E. W., et al., "Some aspects of the biological role of adenosine 3',5'-monophosphate (cyclic AMP)," <i>Circulation</i> , 1968, 37, 279-306	
	FC	Sweetnam, P. M., et al., "The role of receptor binding in drug discovery," <i>J. Natural Products</i> , 1993, 56(4), 441-455	
	FD	Tempest, P. R., et al., "Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection <i>in vivo</i> ," <i>Bio/Technology</i> , 1991, 9, 266-271	
	FE	Torfs, H. et al., "Characterization of a receptor for insect tachykinin-like peptide agonists by functional expression in a stable <i>Drosophila</i> Schneider 2 Cell Line", <i>J. Neurochem.</i> , 2000, 74, 2182-2189	
	FF	Trejo, J., et al., "The cloned thrombin receptor is necessary and sufficient for activation of mitogen-activated protein kinase and mitogenesis in mouse lung fibroblasts," <i>J. Biol. Chem.</i> , 1996, 271, 21536-21541	
	FG	Turgeon, V. L., et al., "Thrombin perturbs neurite outgrowth and induces apoptotic cell death in enriched chick spinal motoneuron cultures through caspase activation," <i>J. Neurosci</i> , 1998, 18(17), 6882-6891	
	FH	Ubl, J. J., et al., "Characteristics of thrombin-induced calcium signals in rat astrocytes," <i>Glia</i> , 1997, 21, 361-369	
	FI	Vanden Broeck, "G-protein-coupled receptors in insect cells", <i>Int. Rev. Cytology</i> , 1996, 164, 189-268	
	FJ	Verhoeven, M., et al., "reshaping human antibodies: Grafting an antilysozyme activity," <i>Science</i> , 1988, 239, 1534-1536	
	FK	Wieboldt, R., et al., "Immunoaffinity ultrafiltration with ion spray HPLC/MS for screening small-molecule libraries," <i>Anal. Chem.</i> , 1997, 69(9), 1683-1691	
	FL	Williams, M., "Receptor binding in the drug discovery process," <i>Medicinal Research Reviews</i> , 1991, 11(2), 147-184	
RLi	FM	Wolbring, G., et al., "Inhibition of GTP-utilizing enzymes by tyrophostins," <i>J. Biol. Chem.</i> , 1994, 269(36), 22470-22472	
EXAMINER		Quixiang L	DATE CONSIDERED 9/30/2006

Form PTO-1449 Modified		Docket No. 6297.1cp/ PHRM-0295	Serial No. 09/693,746
List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Applicant Lowery et al.	
		Filing Date October 20, 2000	Group 1623-1646
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
RLi	FN	Wu, H., et al., "Building zinc fingers by selection: toward a therapeutic application," <i>Proc. Natl. Acad. Sci. USA</i> , 1995, 92, 344-348	
	FO	Yoneda, T., et al., "The antiproliferative effects of tyrosine kinase inhibitors tyrphostins on a human squamous cell carcinoma in vitro and in nude mice," <i>Cancer Research</i> , 1991, 51, 4430-4435	
*	FP	Berger et al., "Guide to Molecular Cloning Techniques," in <i>Methods in Enzymology</i> , Academic Press, Inc., San Diego, CA, 1987	
*	FQ	Cobbold, et al., "Aequorin measurements of cytoplasmic free calcium," In: McCormack J.G., et al. (Eds.), <i>Cellular Calcium: A Practical Approach</i> , 1991, Oxford, IRL Press	
*	FR	<i>Current Protocols in Molecular Biology</i> , John Wiley & Sons, NY, 1999	
*	FS	Eisenthal, R. et al., in <i>Enzyme Assays: A Practical Approach</i> , Oxford University Press, 1992	
*	FT	Harlow, E. et al., in <i>ANTIBODIES: A Laboratory Manual</i> , Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1988	
*	FU	Haugland, <i>Handbook of Fluorescent probes and Research Chemicals</i> , 6 th Ed., 1996, Eugene OR: Molecular Probes	
*	FV	Hendix, R.W. (ed.), <i>Lambda II</i> , Cold Spring Harbor Press, Cold Spring Harbor, NY, 1980	
*	FW	Hershey, A. D. (ed.), <i>The Bacteriophage Lambda</i> , Cold Spring Harbor Press, Cold Spring Harbor, NY, 1973	
*	FX	Kruse et al. (eds.), in <i>Tissue Culture</i> , Academic Press, 1973	
*	FY	O'Rielly et al. (eds.), in <i>Baculovirus Expression Vectors: A Laboratory Manual</i> , W.H. Freeman and Company, New York, 1992	
RLi	FZ	Sambrook et al., in <i>Molecular Cloning: A Laboratory Manual</i> , second edition, Cold Spring Harbor Press, Cold Spring Harbor, NY, 1989	
EXAMINER		<i>Reixag</i>	DATE CONSIDERED 9/3/96

A copy of this reference will not be forwarded to the U.S. Patent and Trademark Office since it is believed to be too voluminous and easily obtainable by the Examiner.

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office				Docket No. 6297.1cp/ PHRM-0295		Serial No. 09/693,746	
				Applicant Lowery et al.			
				Filing Date October 20, 2000		Group 1623 1646	
U. S. PATENT DOCUMENTS							
Examiner Initial		Document No.	Date	Name	Class	Subclass	
RLi	GA	4,343,940	08/10/82	Kreighbaum et al.	544	283	
	GB	4,399,216	08/16/83	Axel et al.	435	6	
	GC	4,447,608	05/08/84	Jones et al.	544	287	
	GD	4,683,195	07/28/87	Mullis et al.	435	6	
	GE	4,683,202	07/28/87	Mullis	435	91	
	GF	4,757,072	07/12/88	Kabbe et al.	514	257	
	GG	4,879,236	11/07/89	Smith et al.	435	235	
	GH	5,217,999	06/08/93	Levitzki et al.	514	613	
	GI	5,302,606	04/12/94	Spada et al.	514	357	
RLi	GJ	5,316,553	05/31/94	Kaul et al.	8	639	
FOREIGN PATENT DOCUMENTS							
Examiner Initial		Document No.	Date	Country	Translation YES NO		
RLi	GK	0 367 566	05/09/90	EPO			
	GL	0 520 722	12/30/92	EPO			
	GM	0 562 734	09/29/93	EPO			
**	GN	0 566 266		EPO			
	GO	91/09955	07/11/91	WO			
	GP	91/15495	10/17/91	WO			
RLi	GQ	92/21660	12/10/92	WO			
EXAMINER <i>Rushling Jr</i>				DATE CONSIDERED 9/3/2006			

*A copy of this patent will not be forwarded to the Patent and Trademark Office as this patent is not to be published and has been withdrawn

Form PTO-1449 Modified				Docket No. 6297.1cp/ PHRM-0295		Serial No. 09/693,746	
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)				Applicant Lowery et al.			
				Filing Date October 20, 2000		Group 1623 1646	
U. S. PATENT DOCUMENTS							
Examiner Initial		Document No.	Date	Name	Class	Subclass	
RLi	✓GR	5,330,992	07/19/94	Eissenstat et al.	514	312	
RLI	✓GS	5,585,277	12/17/96	Bowie et al.	436	518	
RLi	✓GT	5,880,141	03/09/99	Tang et al.	514	339	
FOREIGN PATENT DOCUMENTS							
Examiner Initial		Document No.	Date	Country	Translation YES NO		
RLi	✓GU	91/18982	12/12/91	WO			
	✓GV	92/20642	11/26/92	WO			
	✓GW	92/20808	11/26/92	WO			
	✓GX	93/11236	06/10/93	WO			
	✓GY	94/03427	02/17/94	WO			
	✓GZ	94/12650	06/09/94	WO			
	✓HA	94/14808	07/07/94	WO			
	✓HB	95/20652	08/03/95	WO			
	✓HC	96/22976	08/01/96	WO			
	✓HD	97/09433	03/13/97	WO			
RLi	✓HE	98/37177	08/27/98	WO			
EXAMINER <i>Rushing L.</i>				DATE CONSIDERED 9/30/2006			

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. PHRM-0295/ 6297.1CP	Serial No. 09/693,746
		Applicant David E. Lowery, et al.	
		Filing Date October 20, 2000	Group 1646
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
RLi	HF	Adams, M.D., et al., "The genome sequence of drosophila melanogaster," <i>EMBL/GenBank/DDBJ</i> , XP-002176201, March 21, 2000, 3 pages	
	HG	Alcedo, J., et al., "The drosophila smoothened gene encodes a seven-pass membrane protein, a putative receptor for the hedgehog signal," <i>Cell</i> , XP-002166694, July 26, 1996, 86, 221-232	
	HH	Celniker, S.E., et al., "Drosophila melanogaster, chromosome X, region 17C-17E," <i>EMBL</i> , XP-002176202, October 22, 1999, 2 pages	
	HI	Celniker, S.E., et al., "Drosophila melanogaster, chromosome 2R, region 42A8- 42A16, P1 clones DS06954 and DS05325," <i>EMBL</i> , XP-002176200, March 24, 1999, 2 pages	
	HJ	Celniker, et al., "Drosophila melanogaster, chromosome 3R, region 83D-83D, BAC clone BACR26C09," <i>EMBL</i> , XP-002176198, September 17, 1999, 2 pages	
	HK	Muzny, D.M., et al., "Drosophila melanogaster clone RPC198-10L1," <i>EMBL</i> , XP- 002166695, August 23, 1999, 3 pages	
	HL	Muzny, D.M., et al., "Drosophila melanogaster clone RPC198-23M20," <i>EMBL</i> , xP- 002176199, August 23, 1999, 3 pages	
	HM	Nichols, R., "Isolation and structural characterization of drosophila TDVDHVFLRF amide and FMRF amide-containing neural peptides," <i>Medline</i> , XP-002166696, 1992, 1 page	
	HN	Taghert, P.H., et al., "Interspecific comparison of a <i>drosophila</i> gene encoding FMRF amide-related neuropeptides," <i>J. Neuroscience, USA</i> , 1990, 10(6), 1929-1942	
✓	HO	Copy of PCT International Search Report dated October 29, 2001	
RLi			
EXAMINER RLi		DATE CONSIDERED 9/30/2006	

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office				Docket No. PHRM-0295/ 6297.1CP		Serial No. 09/693,746	
				Applicant David E. Lowery, et al.			
				Filing Date October 20, 2000		Group 1646	
U. S. PATENT DOCUMENTS							
Examiner Initial		Document No.	Date	Name	Class	Subclass	
RL	HP	5,753,615	05/19/98	Thorpe, et al.	514	14	
FOREIGN PATENT DOCUMENTS							
Examiner Initial		Document No.	Date	Country	Translation YES NO		
EXAMINER				<i>Rundberg L</i>		DATE CONSIDERED	
						9/30/2006	

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Complete if Known

Application Number	10/736,048
Filing Date	December 15, 2003
First Named Inventor	David E. Lowery
Art Unit	To Be Determined
Examiner Name	To Be Determined
Attorney Docket Number	6297.1 DV1/PHRM0002-104

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature	<i>Ruiyang Lu</i>	Date Considered	9/30/2006
-----------------------	-------------------	--------------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/736,048
				Filing Date	December 15, 2003
				First Named Inventor	David E. Lowery
				Art Unit	To Be Determined
				Examiner Name	To Be Determined
				Attorney Docket Number	6297.1 DV1/PHRM0002-104
(Use as many sheets as necessary)					
Sheet	2	of	2		

[illegible]

Examiner Signature	<i>Russling Li</i>	Date Considered	9/30/2006
--------------------	--------------------	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b(08-03)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/736,048		
		Filing Date	December 15, 2003		
		First Named Inventor	David E. Lowery		
		Art Unit	1646		
		Examiner Name	Li, Ruixiang		
Sheet	1	of	1	Attorney Docket Number	PHRM0002-104

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RLi	1	Li et al., "Cloning, heterologous expression and developmental regulation of a Drosophila receptor for tachykinin-like peptides," <i>EMBO J</i> (1991) 10(11):3221-3229.	
	2	Ngo et al., <i>The Protein Folding Problem and Tertiary Structure Prediction</i> , pp. 492-495 (1994).	
↓	3	Schoneberg et al., "Mutant G-protein-coupled receptors as a cause of human diseases," <i>Pharmacology and Therapeutics</i> , (2004) 104(3):173-206.	
RLi	4	Wells et al., "Additivity of mutational effects in proteins," <i>Biochemistry</i> (1990) 29(37):8509-8517.	

Examiner Signature	<i>Ruixiang Li</i>	Date Considered	9/3-12-06
-----------------------	--------------------	--------------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08a (08-03)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/736,048
Filing Date	December 15, 2003
First Named Inventor	David E. Lowery
Art Unit	1646
Examiner Name	Ruixiang Li
Attorney Docket Number	PHRM0002-104 (6297.1.DV1)

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication/Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
RLi	1	US-6,703,491	03-09-2004	Homburger et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date/Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				

Examiner Signature	Ruixiang Li	Date Considered	9/30/2006
-----------------------	-------------	--------------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/736,048
		Filing Date	December 15, 2003
		First Named Inventor	David E. Lowery
		Art Unit	1646
		Examiner Name	Ruixiang Li
Sheet 2 of 2	Attorney Docket Number	PHRM0002-104 (6297.1.DV1)	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RLi	2	Howard et al., "Orphan G-protein-coupled receptors and natural ligand discovery," <i>Trends Pharmacol Sci</i> (2001) 22(3):132-140.	
	3	Mickle et al., "Genotype-phenotype relationships in cystic fibrosis," <i>Med Clin North Am</i> (2000) 84(3):597-607.	
	4	Skolnick et al., "From genes to protein structure and function: novel applications of computational approaches in the genomic era," <i>Trends Biotechnol</i> (2000) 18(1):34-9.	
	5	Voet et al. <i>Biochemistry</i> , John Wiley & Sons, New York (1990), pp. 126-129 and pp. 228-234.	
RLi	6	Yan et al., "Two-amino acid molecular switch in an epithelial morphogen that regulates binding to two distinct receptors," <i>Science</i> (2000) 290(5491):523-527.	

Examiner Signature	<i>Ruixiang Li</i>	Date Considered	9/30/2006
--------------------	--------------------	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Notice of References Cited	Application/Control No. 09/693,746	Applicant(s)/Patent Under Reexamination LOWERY ET AL.	
	Examiner Joseph F Murphy	Art Unit 1646	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
RLi	U	Voet et al. Biochemistry. 1990. John Wiley & Sons, Inc., pages 126-128 and 228-234
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Revising Lw 9/30/2006